DK0828513T3 - Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister - Google Patents

Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister

Info

Publication number
DK0828513T3
DK0828513T3 DK95918111T DK95918111T DK0828513T3 DK 0828513 T3 DK0828513 T3 DK 0828513T3 DK 95918111 T DK95918111 T DK 95918111T DK 95918111 T DK95918111 T DK 95918111T DK 0828513 T3 DK0828513 T3 DK 0828513T3
Authority
DK
Denmark
Prior art keywords
parkinsonism
treatment
selective nmda
nmda antagonists
combination preparations
Prior art date
Application number
DK95918111T
Other languages
English (en)
Inventor
Bertrand L Chenard
Frank S Menniti
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0828513T3 publication Critical patent/DK0828513T3/da

Links

Classifications

    • G—PHYSICS
    • G10—MUSICAL INSTRUMENTS; ACOUSTICS
    • G10H—ELECTROPHONIC MUSICAL INSTRUMENTS; INSTRUMENTS IN WHICH THE TONES ARE GENERATED BY ELECTROMECHANICAL MEANS OR ELECTRONIC GENERATORS, OR IN WHICH THE TONES ARE SYNTHESISED FROM A DATA STORE
    • G10H5/00—Instruments in which the tones are generated by means of electronic generators
    • G10H5/10—Instruments in which the tones are generated by means of electronic generators using generation of non-sinusoidal basic tones, e.g. saw-tooth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acoustics & Sound (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Multimedia (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
DK95918111T 1995-05-26 1995-05-26 Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister DK0828513T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB1995/000398 WO1996037226A2 (en) 1995-05-26 1995-05-26 Combinations for the treatment of parkinsonism containing selective nmda antagonists
HU9601419A HUP9601419A3 (en) 1995-05-26 1996-05-24 Synergetic pharmaceutical compositions for treating parkinson-disease

Publications (1)

Publication Number Publication Date
DK0828513T3 true DK0828513T3 (da) 2004-04-13

Family

ID=89994003

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95918111T DK0828513T3 (da) 1995-05-26 1995-05-26 Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister

Country Status (26)

Country Link
US (1) US6258827B1 (da)
EP (1) EP0828513B1 (da)
JP (1) JPH11505828A (da)
CN (1) CN1159325A (da)
AT (1) ATE258067T1 (da)
AU (1) AU696258B2 (da)
BR (1) BR9602485A (da)
CA (1) CA2219911C (da)
CO (1) CO4700422A1 (da)
CZ (1) CZ283979B6 (da)
DE (1) DE69532482T2 (da)
DK (1) DK0828513T3 (da)
ES (1) ES2211904T3 (da)
FI (1) FI974323L (da)
HU (1) HUP9601419A3 (da)
IL (1) IL118328A (da)
MX (1) MX9709112A (da)
NO (1) NO962130L (da)
NZ (1) NZ286656A (da)
PL (1) PL314413A1 (da)
PT (1) PT828513E (da)
RU (1) RU2176145C2 (da)
SG (1) SG45479A1 (da)
TR (1) TR199600436A2 (da)
TW (1) TW470740B (da)
WO (1) WO1996037226A2 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
BR9814867A (pt) * 1997-10-24 2000-10-03 Warner Lambert Co Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
AU1153601A (en) 1999-10-29 2001-05-08 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole NMDA NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
MXPA03007621A (es) 2001-02-23 2003-12-04 Merck & Co Inc Antagonistas nr2b de n-metil-d-aspartato no arilheterociclicos n-sustituidos.
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
JP2005506292A (ja) 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
EP1390034A4 (en) 2001-04-03 2005-07-13 Merck & Co Inc N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10142176A1 (de) * 2001-08-29 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten
EP1472248A1 (en) 2002-01-17 2004-11-03 Eli Lilly And Company Modulators of acetylcholine receptors
US6743921B2 (en) * 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
JP2006504741A (ja) * 2002-10-08 2006-02-09 アラーガン、インコーポレイテッド 痴呆およびパーキンソン病の処置における（２−イミダゾリン−２−イルアミノ）キノキサリンの使用方法
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
WO2005023197A2 (en) * 2003-09-04 2005-03-17 Board Of Regents, The University Of Texas System Methods and compositions for the prevention and treatment of genitourinary disorders, including pre-term labor and leiomyomas
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
WO2006042249A2 (en) * 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methods and compositions for treating migraine pain
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
RU2281695C1 (ru) * 2004-12-24 2006-08-20 Дмитрий Владимирович Похабов Способ лечения болезни паркинсона
EP1838705A2 (en) * 2005-01-13 2007-10-03 Neurosearch A/S 3,8-substituted 8-aza-bicyclo [3.2.1] octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20070118044A1 (en) * 2005-07-18 2007-05-24 Mega Elektroniikka Oy Method and device for identifying; measuring and analyzing abnormal neurological responses
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
RU2324492C1 (ru) * 2006-12-04 2008-05-20 Общество с ограниченной ответственностью "Березовый мир" Средство для профилактики и лечения болезни паркинсона
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
RU2393860C2 (ru) * 2008-05-30 2010-07-10 Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию" Использование тизанидина в качестве корректора лекарственного паркинсонизма
RU2540470C9 (ru) * 2008-06-06 2015-07-20 Фарма Ту Б Лтд. Фармацевтические композиции для лечения болезни паркинсона
RU2386458C1 (ru) * 2008-09-04 2010-04-20 Государственное Учреждение Научный Центр Неврологии Российской Академии Медицинских Наук Способ лечения болезни паркинсона
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
AU2013251079B2 (en) * 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
PL3777833T3 (pl) 2014-03-13 2024-03-25 Neuroderm Ltd. Kompozycje inhibitorów dekarboksylazy dopa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
HU222726B1 (hu) 1990-02-06 2003-09-29 Pfizer, Inc., Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
FI934566L (fi) 1991-04-18 1993-10-15 Pfizer Prodrug-estrar av fenol-2-piperidino-1-alkanoler
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
RU2000114C1 (ru) * 1991-07-18 1993-09-07 Васильев В.Н. Способ Васильева В.Н. лечени заболеваний, св занных с недостаточностью дофаминового обмена

Also Published As

Publication number Publication date
WO1996037226A2 (en) 1996-11-28
HUP9601419A2 (en) 1997-09-29
PT828513E (pt) 2004-05-31
CN1159325A (zh) 1997-09-17
BR9602485A (pt) 1998-04-22
HUP9601419A3 (en) 1998-01-28
MX9709112A (es) 1998-02-28
TR199600436A2 (tr) 1996-12-21
RU2176145C2 (ru) 2001-11-27
SG45479A1 (en) 1998-01-16
AU5451996A (en) 1996-12-05
PL314413A1 (en) 1996-12-09
DE69532482D1 (de) 2004-02-26
NO962130D0 (no) 1996-05-24
CZ283979B6 (cs) 1998-07-15
EP0828513A2 (en) 1998-03-18
DE69532482T2 (de) 2004-11-25
ATE258067T1 (de) 2004-02-15
ES2211904T3 (es) 2004-07-16
JPH11505828A (ja) 1999-05-25
CA2219911C (en) 2004-07-27
AU696258B2 (en) 1998-09-03
US6258827B1 (en) 2001-07-10
FI974323A0 (fi) 1997-11-25
NZ286656A (en) 2001-03-30
FI974323A7 (fi) 1997-11-25
NO962130L (no) 1996-11-27
CZ152496A3 (cs) 1998-04-15
FI974323L (fi) 1997-11-25
WO1996037226A3 (en) 1996-12-27
EP0828513B1 (en) 2004-01-21
HU9601419D0 (en) 1996-07-29
CO4700422A1 (es) 1998-12-29
IL118328A (en) 2001-06-14
TW470740B (en) 2002-01-01
IL118328A0 (en) 1996-09-12
CA2219911A1 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
FI974323A0 (fi) Selektiivisiä NMDA-antagonisteja sisältäviä yhdistelmiä parkinsonismin hoitoa varten
DE60022050T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
DE69720745D1 (de) Therapeutische kombinationen von rar-antagonisten und rxr-agonisten
ATE230989T1 (de) Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
PL338352A1 (en) Derivatives of 1-(n-phenylaminoalkyl)-piperazine substituted at position 2 of its phenyl ring
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE69926794D1 (de) Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen
BR9814867A (pt) Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
EA200401230A1 (ru) Азабициклические, азатрициклические и азаспироциклические производные аминоциклогексана в качестве антагонистов рецепторов nmda, 5ht и нейронных никотиновых рецепторов
MY118944A (en) Synergistic treatment for parkinsonism
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
EP0900567A3 (en) Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
SE9501773D0 (sv) New use